- Doctor Gets First U.S. Lung-Liver Transplant for Advanced Lung Cancer
- Good Sleep Can Make You Feel Young
- U.S. Mpox Cases Rising Again as Vaccinations Lag
- Binge Drinking Boosts Heart Risks, Especially for Women
- Too Often, Nearby Defibrillators Go Unused on People in Cardiac Arrest
- Stressed? Some Genes Could Raise Your Heart Attack Risk
- Puerto Rico Declares Dengue Epidemic as Cases Climb
- Hormonal Meds for Birth Control, Menopause Linked to Brain Tumors
- These 3 Factors Make Your Brain More Vulnerable to Dementia
- High Rate of Suicidal Thoughts Among Black Men in Rural America: Study
New Antibiotic Avycaz Approved
The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, including the kidneys.
Avycaz contains the previously approved antibiotic ceftazidime, and the newer antibacterial drug avibactam, the agency said in a news release.
Approved to help combat antibacterial resistance, Avycaz is sanctioned for people who have limited or no other treatment options, the FDA said.
The most common side effects identified during clinical testing included vomiting, nausea, constipation and anxiety. Users with poor kidney function had more serious adverse reactions including decreased effectiveness and seizures, the agency said. And users allergic to penicillin may be at greater risk of serious skin reactions and anaphylaxis, the FDA warned.
Avycaz is distributed by a subsidiary of Forest Laboratories, based in Cincinnati.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.